July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Anti-VEGF Non-Responders are often short-term responders
Author Affiliations & Notes
  • Saghar Bagheri
    Massachusetts Eye and Ear, Harvard Medical School, Cambridge, Massachusetts, United States
  • Georgios Bontzos
    OMMA Eye Institute, Athens, Greece
  • Larisa Ioannidi
    Eye Clinic, University Hospital of Heraklion, Greece
  • Stamatina Kabanarou
    Department of Ophthalmology, Korgialenio Benakio Hopsital, Athens, Greece
  • Ivana K Kim
    Massachusetts Eye and Ear, Harvard Medical School, Cambridge, Massachusetts, United States
  • Evangelos S Gragoudas
    Massachusetts Eye and Ear, Harvard Medical School, Cambridge, Massachusetts, United States
  • Joan W Miller
    Massachusetts Eye and Ear, Harvard Medical School, Cambridge, Massachusetts, United States
  • IOANNIS DATSERIS
    OMMA Eye Institute, Athens, Greece
  • Miltiadis K. Tsilimbaris
    Eye Clinic, University Hospital of Heraklion, Greece
  • Demetrios Vavvas
    Massachusetts Eye and Ear, Harvard Medical School, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Saghar Bagheri, None; Georgios Bontzos, None; Larisa Ioannidi, None; Stamatina Kabanarou, None; Ivana Kim, Alcon/Novartis (C), Bausch + Lomb (C), Biophytis (C), Castle Biosciences (C); Evangelos Gragoudas, None; Joan Miller, Bausch + Lomb (C), Genentech/Roche (C), Genentech/Roche (R), KalVista Pharmaceuticals (C), Lowy Medical Research Institute (F), ONL Therapeutics (C), ONL Therapeutics (P), ONL Therapeutics (R), Valeant Pharmaceuticals/Mass. Eye and Ear (P), Valeant Pharmaceuticals/Mass. Eye and Ear (R); IOANNIS DATSERIS, None; Miltiadis Tsilimbaris, Alcon Hellas (F), Allergan (F), Bayer Hellas (F), Johnson and Johnson (F), Novartis Hellas (R), Novartis Hellas (C), Novartis Hellas (F), Thea (R); Demetrios Vavvas, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 77. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saghar Bagheri, Georgios Bontzos, Larisa Ioannidi, Stamatina Kabanarou, Ivana K Kim, Evangelos S Gragoudas, Joan W Miller, IOANNIS DATSERIS, Miltiadis K. Tsilimbaris, Demetrios Vavvas; Anti-VEGF Non-Responders are often short-term responders. Invest. Ophthalmol. Vis. Sci. 2019;60(9):77.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The purpose of our study was to investigate the duration of anti-VEGF treatment effect in patients with neovascular age-related macular degeneration (nvAMD), diabetic macular edema (DME) and retinal vein occlusion, and to determine if non- or poor-responders at the standard 4-week interval actually demonstrate a treatment response at an earlier time point.

Methods : This study is a prospective multi-center trial with patients recruited from the Eye Clinic of the University Hospital of Heraklion and from the OMMA Eye Institute in Athens, Greece. Patients received intravitreal anti-VEGF (0.5 mg ranibizumab) injections and subsequently were assessed weekly for a total period of 4-6 weeks by spectral-domain optical coherence tomography (SD-OCT) for reduction in central retinal thickness (CRT) and the presence of intra- and subretinal fluid. Data collected included age, sex, visual acuity, past ocular history, total retinal volume, axial length and lens status.

Results : 52 eyes of 52 patients (mean age 67.8 years, 59.6% female, 54% treatment naive) were assessed. More than half of the eyes (51.5 %) presented with maximal CRT reduction on SD-OCT two-weeks post-injection and almost all had significantly increased CRT at week 4 compared to week 3 or week 2. Eyes that showed no to minimal CRT reduction at week 4 and would have been classified as non-responders in the usual clinical evaluation were found to have CRT reduction at weeks 2 or 3 post-injection. Furthermore, we found a higher proportion of non- and poor responders at week 4 in DME (7 of 12, 58%) compared to nvAMD (6 of 25, 24%) eyes (chi-square 4.194, p=0.0406). The time to maximal CRT reduction was not related to axial length, age, lens status or prior history of injections.

Conclusions : Our study suggests that almost all non-responders or poor responders to anti-VEGF therapy are responders if assessed at an earlier time point such as at week 2 or 3 post-injection. Our study assesses for anti-VEGF treatment response by weekly CRT measurements with SD-OCT and is the first study to describe the treatment response in previously considered non-responders. Further large, prospective studies are needed to optimize dosing intervals and to evaluate whether more frequent anti-VEGF treatment might preserve visual function in this cohort of short-term responders.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Frequency histogram of time to maximal CRT reduction

Frequency histogram of time to maximal CRT reduction

 

Three example patients showing early CRT reduction followed by increase at week 4

Three example patients showing early CRT reduction followed by increase at week 4

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×